Jeffrey Lipman

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5251153/jeffrey-lipman-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

539 papers	24,496 citations	76 h-index	137 g-index
605 ext. papers	29,295 ext. citations	6.2 avg, IF	7.04 L-index

#	Paper	IF	Citations
539	Pharmacodynamics of ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus: Is it a viable treatment option?. *International Journal of Antimicrobial Agents*, **2022**, 106537	14.3	0
538	Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study.. *International Journal of Antimicrobial Agents*, **2022**, 59, 106513	14.3	
537	Evaluation of low-volume plasma sampling for the analysis of meropenem in clinical samples.. *Analytical and Bioanalytical Chemistry*, **2022**, 1	4.4	0
536	Epidemiology and Age-Related Mortality in Critically Ill Patients With Intra-Abdominal Infection or Sepsis: An International Cohort Study.. *International Journal of Antimicrobial Agents*, **2022**, 106591	14.3	0
535	Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0218921	5.9	1
534	A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane-tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 921-933	5.9	2
533	A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients. *Anaesthesia, Critical Care & Pain Medicine*, **2021**, 40, 100970	3	5
532	Early Sequential Microcirculation Assessment In Shocked Patients as a Predictor of Outcome: A Prospective Observational Cohort Study. *Shock*, **2021**, 55, 581-586	3.4	4
531	Re-expansion pulmonary oedema with Takotsubo cardiomyopathy: a rare complication of giant hepatic cyst drainage. *ANZ Journal of Surgery*, **2021**, 91, 2524-2527	1	0
530	Genomic surveillance, characterization and intervention of a polymicrobial multidrug-resistant outbreak in critical care. *Microbial Genomics*, **2021**, 7,	4.4	6
529	Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1104-1115	6.1	5
528	An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. *Annals of Intensive Care*, **2021**, 11, 49	8.9	5
527	Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa. *Drugs in R and D*, **2021**, 21, 203-215	3.4	1
526	Lorazepam challenge test for catatonia. *EMA - Emergency Medicine Australasia*, **2021**, 33, 763-764	1.5	1
525	Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children. *Analytical and Bioanalytical Chemistry*, **2021**, 413, 4483-4491	4.4	0
524	Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations. *European Journal of Drug Metabolism and Pharmacokinetics*, **2021**, 46, 479-485	2.7	1
523	A Multicenter Observational Study Evaluating Outcomes Associated With Antibiotic Combination Versus Monotherapy in Patients With Septic Shock **2021**, 3, e0383		

522	Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units. *Drugs*, **2021**, 81, 1065-1078	12.1	3
521	Microsampling to support pharmacokinetic clinical studies in pediatrics. *Pediatric Research*, **2021**,	3.2	1
520	Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0230720	5.9	0
519	Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa. *Diagnostic Microbiology and Infectious Disease*, **2021**, 100, 115329	2.9	1
518	Optimising Treatment Outcomes for Children and Adults Through Rapid Genome Sequencing of Sepsis Pathogens. A Study Protocol for a Prospective, Multi-Centre Trial (DIRECT). *Frontiers in Cellular and Infection Microbiology*, **2021**, 11, 667680	5.9	1
517	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. *Clinical Infectious Diseases*, **2021**, 72, 1369-1378	11.6	37
516	Ceftriaxone dosing in patients admitted from the emergency department with sepsis. *European Journal of Clinical Pharmacology*, **2021**, 77, 207-214	2.8	2
515	Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. *Clinical Pharmacokinetics*, **2021**, 60, 655-664	6.2	6
514	A narrative review on antimicrobial therapy in septic shock: updates and controversies. *Current Opinion in Anaesthesiology*, **2021**, 34, 92-98	2.9	1
513	Ventilation practices in burn patients-an international prospective observational cohort study.. *Burns and Trauma*, **2021**, 9, tkab034	5.3	0
512	A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. *Therapeutic Drug Monitoring*, **2021**, 43, 747-755	3.2	0
511	Initial antimicrobial management of sepsis. *Critical Care*, **2021**, 25, 307	10.8	14
510	Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Lactamase-Producing spp, , , spp, or : A Pilot Multicenter Randomized Controlled Trial (MERINO-2). *Open Forum Infectious Diseases*, **2021**, 8, ofab387	1	11
509	Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report. *International Journal of Antimicrobial Agents*, **2021**, 58, 106431	14.3	0
508	Global personalization of antibiotic therapy in critically ill patients. *Expert Review of Precision Medicine and Drug Development*, **2021**, 6, 87-93	1.6	0
507	Population pharmacokinetics of intra-peritoneal gentamicin and the impact of varying dwell times on pharmacodynamic target attainment in patients with acute peritonitis undergoing peritoneal dialysis.. *Antimicrobial Agents and Chemotherapy*, **2021**, AAC0167921	5.9	0
506	An international survey of adherence to Surviving Sepsis Campaign Guidelines 2016 regarding fluid resuscitation and vasopressors in the initial management of septic shock.. *Journal of Critical Care*, **2021**,	4	1
505	Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study.. *Clinical Pharmacokinetics*, **2021**, 1	6.2	

504	Pulmonary infections complicating ARDS. *Intensive Care Medicine*, **2020**, 46, 2168-2183	14.5	19
503	An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy. *Pharmaceutical Research*, **2020**, 37, 96	4.5	4
502	Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. *Pharmacotherapy*, **2020**, 40, 713-717	5.8	1
501	Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	2
500	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. *Intensive Care Medicine*, **2020**, 46, 1404-1417	14.5	18
499	Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis. *Expert Opinion on Drug Metabolism and Toxicology*, **2020**, 16, 415-430	5.5	7
498	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. *Clinical Pharmacokinetics*, **2020**, 59, 1027-1036	6.2	5
497	Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers. *Frontiers in Pharmacology*, **2020**, 11, 883	5.6	6
496	Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2633-2640	5.1	3
495	Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg□m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. *Anesthesia and Analgesia*, **2020**, 131, 199-207	3.9	6
494	Integrating multiple genomic technologies to investigate an outbreak of carbapenemase-producing Enterobacter hormaechei. *Nature Communications*, **2020**, 11, 466	17.4	14
493	Antimicrobial-associated harm in critical care: a narrative review. *Intensive Care Medicine*, **2020**, 46, 225-235	14.5	36
492	Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms. *Microorganisms*, **2020**, 8,	4.9	17
491	Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. *International Journal of Antimicrobial Agents*, **2020**, 55, 105943	14.3	6
490	On-Site Therapeutic Drug Monitoring. *Trends in Biotechnology*, **2020**, 38, 1262-1277	15.1	55
489	There is no fire without smoke! Pathophysiology and treatment of inhalational injury in burns: A narrative review. *Anaesthesia and Intensive Care*, **2020**, 48, 114-122	1.1	1
488	International facilitators and barriers to family engagement in the ICU: Results of a qualitative analysis. *Journal of Critical Care*, **2020**, 58, 72-77	4	11
487	□Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 429-433	5.1	25

486	Ventilator-Associated Tracheobronchitis: To Treat or Not to Treat?. *Antibiotics*, **2020**, 9,	4.9	2
485	Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2641-2649	5.1	8
484	β-lactam antibiotic versus combined β-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis. *International Journal of Antimicrobial Agents*, **2020**, 55, 105839	14.3	14
483	Development and validation of LC-MS/MS methods to measure tobramycin and lincomycin in plasma, microdialysis fluid and urine: application to a pilot pharmacokinetic research study. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 274-284	5.9	3
482	Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain. *Antimicrobial Agents and Chemotherapy*, **2020**, 65,	5.9	6
481	A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges. *Antimicrobial Agents and Chemotherapy*, **2020**, 65,	5.9	4
480	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic Hollow-Fiber Infection Model. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	2
479	Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit. *Antibiotics*, **2020**, 9,	4.9	2
478	Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy. *Frontiers in Medicine*, **2020**, 7, 588863	4.9	4
477	Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. *Clinical Pharmacokinetics*, **2020**, 59, 1237-1250	6.2	7
476	Ticarcillin and piperacillin adsorption on to polyethersulfone haemodiafilter membranes in an ex-vivo circuit. *International Journal of Antimicrobial Agents*, **2020**, 56, 106058	14.3	1
475	When not to start antibiotics: avoiding antibiotic overuse in the intensive care unit. *Clinical Microbiology and Infection*, **2020**, 26, 35-40	9.5	19
474	Pharmacokinetics of Total and Unbound Cefazolin during Veno-Arterial Extracorporeal Membrane Oxygenation: A Case Report. *Chemotherapy*, **2019**, 64, 115-118	3.2	2
473	Lefamulin. Comment on: "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. , 2019, , 270". *Microorganisms*, **2019**, 7,	4.9	8
472	Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion. *International Journal of Antimicrobial Agents*, **2019**, 54, 741-749	14.3	8
471	The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence?. *European Journal of Clinical Microbiology and Infectious Diseases*, **2019**, 38, 637-647	5.3	6
470	Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. *Critical Care*, **2019**, 23, 205	10.8	15
469	Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. *Expert Review of Clinical Pharmacology*, **2019**, 12, 623-634	3.8	17

468	Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia. *Journal of Infection and Chemotherapy*, **2019**, 25, 503-508	2.2	5
467	Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study. *Journal of Pharmaceutical and Biomedical Analysis*, **2019**, 169, 288-292	3.5	4
466	Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study. *Journal of Critical Care*, **2019**, 52, 75-79	4	17
465	In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration. *International Journal of Antimicrobial Agents*, **2019**, 54, 261-264	14.3	6
464	Challenges in the management of septic shock: a narrative review. *Intensive Care Medicine*, **2019**, 45, 420-433	14.5	22
463	A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy. *Clinical Pharmacokinetics*, **2019**, 58, 263-270	6.2	
462	Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. *Microorganisms*, **2019**, 7,	4.9	37
461	What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. *Clinical Pharmacokinetics*, **2019**, 58, 1407-1443	6.2	47
460	A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. *New England Journal of Medicine*, **2019**, 381, 328-337	59.2	69
459	Population pharmacokinetics of ticarcillin in critically ill patients receiving extended daily diafiltration. *International Journal of Antimicrobial Agents*, **2019**, 54, 351-355	14.3	1
458	Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	25
457	Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeS", a multinational observational cohort study and ESICM Trials Group Project. *Intensive Care Medicine*, **2019**, 45, 1703-1717	14.5	40
456	Defining optimal dosing of ciprofloxacin in patients with septic shock. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1662-1669	5.1	11
455	1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients. *Open Forum Infectious Diseases*, **2019**, 6, S574-S575	1	78
454	Amoxicillin-Clavulanate Dosing in the Intensive Care Unit: The Additive Effect of Renal Replacement Therapy in a Patient with Normal Kidney Function. *Chemotherapy*, **2019**, 64, 173-176	3.2	3
453	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2019**, 64,	5.9	7
452	A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study. *Analytical and Bioanalytical Chemistry*, **2019**, 411, 7831-7840	4.4	7
451	A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. *Antimicrobial Agents and Chemotherapy*, **2019**, 64,	5.9	18

450	Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). *Therapeutic Drug Monitoring*, **2019**, 41, 703-713	3.2	4
449	Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 432-441	5.1	32
448	Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review. *International Journal of Antimicrobial Agents*, **2019**, 53, 234-245	14.3	25
447	Infections by multidrug-resistant Gram-negative Bacteria: WhatIs new in our arsenal and whatIs in the pipeline?. *International Journal of Antimicrobial Agents*, **2019**, 53, 211-224	14.3	46
446	Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis. *International Journal of Antimicrobial Agents*, **2019**, 53, 137-142	14.3	7
445	A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. *Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine*, **2019**, 21, 63-68	2.8	9
444	Survey of critical care practice in Australian and New Zealand burn referral centres. *Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine*, **2019**, 21, 303-304	2.8	1
443	Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 1647-1650	5.1	12
442	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	11
441	Utility of community-acquired pneumonia severity scores in guiding disposition from the emergency department: Intensive care or short-stay unit?. *EMA - Emergency Medicine Australasia*, **2018**, 30, 538-546	1.5	4
440	Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	12
439	Re: Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?L Pharmacokinetic/pharmacodynamic considerations. *Clinical Microbiology and Infection*, **2018**, 24, 666-667	9.5	1
438	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. *Intensive Care Medicine*, **2018**, 44, 189-196	14.5	65
437	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli. *Diagnostic Microbiology and Infectious Disease*, **2018**, 91, 69-76	2.9	3
436	Individualising Therapy to Minimize Bacterial Multidrug Resistance. *Drugs*, **2018**, 78, 621-641	12.1	32
435	Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. *Bioanalysis*, **2018**, 10, 407-423	2.1	20
434	Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. *International Journal of Antimicrobial Agents*, **2018**, 52, 151-157	14.3	13
433	Maximally effective dosing regimens of meropenem in patients with septic shock. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 191-198	5.1	29

432	A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. *Journal of Pharmaceutical and Biomedical Analysis*, **2018**, 148, 324-333	3.5	15
431	The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: An appraisal utilizing antibiotics. *Advanced Drug Delivery Reviews*, **2018**, 123, 65-74	18.5	27
430	Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?. *Clinical Pharmacokinetics*, **2018**, 57, 439-454	6.2	14
429	Characteristics, treatment and outcomes for all emergency department patients fulfilling criteria for septic shock: a prospective observational study. *European Journal of Emergency Medicine*, **2018**, 25, 97-104	2.3	7
428	A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration. *International Journal of Antimicrobial Agents*, **2018**, 52, 506-509	14.3	5
427	Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 3087-3094	5.1	63
426	Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	18
425	New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods. *Expert Opinion on Drug Metabolism and Toxicology*, **2018**, 14, 693-708	5.5	8
424	Optimised dosing of vancomycin in critically ill Indigenous Australian patients with severe sepsis. *Anaesthesia and Intensive Care*, **2018**, 46, 374-380	1.1	7
423	Prevalence of augmented renal clearance and performance of glomerular filtration estimates in Indigenous Australian patients requiring intensive care admission. *Anaesthesia and Intensive Care*, **2018**, 46, 42-50	1.1	8
422	A comparison between raw and predicted mortality in a paediatric intensive care unit in South Africa. *BMC Research Notes*, **2018**, 11, 829	2.3	2
421	The Statistical Curriculum Within Randomized Controlled Trials in Critical Illness. *Critical Care Medicine*, **2018**, 46, 1985-1990	1.4	2
420	The authors reply. *Critical Care Medicine*, **2018**, 46, e725-e726	1.4	
419	Strategies to reduce inappropriate laboratory blood test orders in intensive care are effective and safe: a before-and-after quality improvement study. *Anaesthesia and Intensive Care*, **2018**, 46, 313-320	1.1	8
418	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. *Intensive Care Medicine Experimental*, **2018**, 6, 17	3.7	4
417	Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. *Open Forum Infectious Diseases*, **2018**, 5, ofy313	1	120
416	Patient and family engagement in the ICU: Report from the task force of the World Federation of Societies of Intensive and Critical Care Medicine. *Journal of Critical Care*, **2018**, 48, 251-256	4	40
415	Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury. *Journal of Critical Care*, **2018**, 47, 15-20	4	3

414	Augmented Renal Clearance in Traumatic Brain Injury: A Single-Center Observational Study of Atrial Natriuretic Peptide, Cardiac Output, and Creatinine Clearance. *Journal of Neurotrauma*, **2017**, 34, 137-144	5.4	33
413	Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	33
412	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. *Intensive Care Medicine*, **2017**, 43, 1187-1197	14.5	66
411	Pyroglutamate (5-oxoproline) measured with hydrophilic interaction chromatography (HILIC) tandem mass spectrometry in acutely ill patients. *Clinica Chimica Acta*, **2017**, 466, 72-77	6.2	2
410	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	20
409	Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. *International Journal of Antimicrobial Agents*, **2017**, 49, 624-630	14.3	56
408	Dosing antibiotic prophylaxis during cardiopulmonary bypass-a higher level of complexity? A structured review. *International Journal of Antimicrobial Agents*, **2017**, 49, 395-402	14.3	13
407	"Salvage treatment" for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. *Intensive Care Medicine*, **2017**, 43, 1164-1166	14.5	6
406	Factors influencing psychological, social and health outcomes after major burn injuries in adults: cohort study protocol. *BMJ Open*, **2017**, 7, e017545	3	13
405	Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. *British Journal of Anaesthesia*, **2017**, 118, 876-882	5.4	10
404	Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	30
403	Antibiotic dosing for multidrug-resistant pathogen pneumonia. *Current Opinion in Infectious Diseases*, **2017**, 30, 231-239	5.4	6
402	Right Dose, Right Now: Customized Drug Dosing in the Critically Ill. *Critical Care Medicine*, **2017**, 45, 331-336	5.4	45
401	What's new in pharmacokinetics of antimicrobials in AKI and RRT?. *Intensive Care Medicine*, **2017**, 43, 904-906	14.5	5
400	Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. *International Journal of Antimicrobial Agents*, **2017**, 49, 589-594	14.3	34
399	Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. *Clinical Pharmacokinetics*, **2017**, 56, 1057-1068	6.2	25
398	An LC-MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent. *Bioanalysis*, **2017**, 9, 911-924	2.1	11
397	Detailed assessment of benefits and risks of retrievable inferior vena cava filters on patients with complicated injuries: the da Vinci multicentre randomised controlled trial study protocol. *BMJ Open* , **2017**, 7, e016747	3	9

396	Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	13
395	A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples. *Biomedical Chromatography*, **2017**, 31, e4030	1.7	1
394	Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients. *International Journal of Antimicrobial Agents*, **2017**, 50, 227-231	14.3	14
393	Hemoglobin concentrations and RBC transfusion thresholds in patients with acute brain injury: an international survey. *Critical Care*, **2017**, 21, 159	10.8	24
392	Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. *Clinical Microbiology and Infection*, **2017**, 23, 533-541	9.5	36
391	Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	16
390	Does Furosemide Increase Oxidative Stress in Acute Kidney Injury?. *Antioxidants and Redox Signaling*, **2017**, 26, 221-226	8.4	16
389	Interpretation of Care Guidelines for Obese Women in Labor: Intergroup Language and Social Identity. *Journal of Language and Social Psychology*, **2017**, 36, 388-414	1.2	1
388	Systemic Inflammatory Response Syndrome, Quick Sequential Organ Function Assessment, and Organ Dysfunction: Insights From a Prospective Database of ED Patients With Infection. *Chest*, **2017**, 151, 586-596	5.3	178
387	Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 206-14	5.9	11
386	Understanding PK/PD. *Intensive Care Medicine*, **2016**, 42, 1797-1800	14.5	38
385	Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study). *Peritoneal Dialysis International*, **2016**, 36, 421-6	2.8	8
384	Uncertainty in Antibiotic Dosing in Critically Ill Neonate and Pediatric Patients: Can Microsampling Provide the Answers?. *Clinical Therapeutics*, **2016**, 38, 1961-75	3.5	19
383	Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2902-8	5.1	7
382	Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 7402-7406	5.9	13
381	Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis. *International Journal of Antimicrobial Agents*, **2016**, 48, 748-752	14.3	17
380	Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLC-MS/MS: application to a pilot pharmacokinetic study in humans. *Biomedical Chromatography* , **2016**, 30, 872-9	1.7	16
379	We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how?. *Critical Care*, **2016**, 20, 163	10.8	6

378	"Not out of the woods"--a wifeIs perspective: bedside communication. *Intensive Care Medicine*, **2016** , 42, 446-447	14.5	4
377	Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2509-20	5.1	26
376	CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. *Trials*, **2016**, 17, 170	2.8	45
375	Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4901-9	5.9	19
374	Severity Scores in Emergency Department Patients With Presumed Infection: A Prospective Validation Study. *Critical Care Medicine*, **2016**, 44, 539-47	1.4	36
373	Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. *Intensive Care Medicine*, **2016**, 42, 1535-1545	14.5	172
372	Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. *Peritoneal Dialysis International*, **2016**, 36, 415-20	2.8	5
371	What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 696-702	5.1	24
370	In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 827-32	5.9	13
369	Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 681-91	10.2	192
368	Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. *International Journal of Antimicrobial Agents*, **2016**, 47, 259-68	14.3	63
367	The use and risks of antibiotics in critically ill patients. *Expert Opinion on Drug Safety*, **2016**, 15, 667-78	4.1	16
366	SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. *BMC Infectious Diseases*, **2016**, 16, 103	4	11
365	Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1643-50	5.1	12
364	A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. *Clinical Infectious Diseases*, **2016**, 62, 1009-1017	11.6	111
363	Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 464-70	5.1	23
362	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 196-207	5.1	104
361	Anaesthetic management of obese parturients: what is the evidence supporting practice guidelines?. *Anaesthesia and Intensive Care*, **2016**, 44, 552-9	1.1	2

360	Bugs, genes, and the intensive care unit. *Journal of Thoracic Disease*, **2016**, 8, E788-90	2.6	1
359	AnaesthetistsLexperiences with the early labour epidural recommendation for obese parturients: a qualitative study. *Anaesthesia and Intensive Care*, **2016**, 44, 620-7	1.1	3
358	EPHA4-FC TREATMENT REDUCES ISCHEMIA/REPERFUSION-INDUCED INTESTINAL INJURY BY INHIBITING VASCULAR PERMEABILITY. *Shock*, **2016**, 45, 184-91	3.4	10
357	The Value of E-Learning for the Prevention of Healthcare-Associated Infections. *Infection Control and Hospital Epidemiology*, **2016**, 37, 1052-9	2	13
356	Therapeutic drug monitoring of anti-infective agents in critically ill patients. *Expert Review of Clinical Pharmacology*, **2016**, 9, 961-79	3.8	77
355	Is inhaled prophylactic heparin useful for prevention and Management of Pneumonia in ventilated ICU patients?: The IPHIVAP investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group. *Journal of Critical Care*, **2016**, 34, 95-102	4	15
354	New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4750-6	5.9	35
353	Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4577-84	5.9	27
352	Determinants of Urinary Output Response to IV Furosemide in Acute Kidney Injury: A Pharmacokinetic/Pharmacodynamic Study. *Critical Care Medicine*, **2016**, 44, e923-9	1.4	15
351	Is there a role for microsampling in antibiotic pharmacokinetic studies?. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 601-14	5.5	16
350	Should β-lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacists. *International Journal of Antimicrobial Agents*, **2016**, 47, 436-8	14.3	13
349	Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 6550-6557	5.9	26
348	Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients. *Clinical Infectious Diseases*, **2016**, 63, 1463-1469	11.6	29
347	Effect of time on recovery of plasma microsamples for the quantitative determination of vancomycin. *Bioanalysis*, **2016**, 8, 2235-2242	2.1	25
346	Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. *Intensive Care Medicine*, **2016**, 42, 1958-1969	14.5	81
345	Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. *International Journal of Antimicrobial Agents*, **2016**, 48, 542-546	14.3	23
344	Use of neostigmine for acute colonic pseudo-obstruction in a patient receiving dexmedetomidine. *Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine*, **2016**, 18, 59-61	2.8	1
343	Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?. *Minerva Anestesiologica*, **2016**, 82, 957-65	1.9	19

342	Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol. *Journal of Clinical Microbiology*, **2015**, 53, 1324-30	9.7	32
341	From the intensive care bed: we need to hear and listen. *Intensive Care Medicine*, **2015**, 41, 921-2	14.5	1
340	A meta-analysis of ventriculostomy-associated cerebrospinal fluid infections. *BMC Infectious Diseases*, **2015**, 15, 3	4	70
339	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. *Critical Care*, **2015**, 19, 33	10.8	83
338	Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. *International Journal of Antimicrobial Agents*, **2015**, 46, 39-44	14.3	23
337	Influence of sustained low-efficiency diafiltration (SLED-f) on interstitial fluid concentrations of fluconazole in a critically ill patient: Use of microdialysis. *International Journal of Antimicrobial Agents*, **2015**, 46, 121-4	14.3	5
336	A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 4689-94	5.9	16
335	A validated method for the quantification of fosfomycin on dried plasma spots by HPLC-MS/MS: application to a pilot pharmacokinetic study in humans. *Journal of Pharmaceutical and Biomedical Analysis*, **2015**, 115, 509-14	3.5	18
334	A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 1298-305	10.2	147
333	The authors reply. *Critical Care Medicine*, **2015**, 43, e101-2	1.4	
332	Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. *International Journal of Antimicrobial Agents*, **2015**, 46, 249-53	14.3	46
331	Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 3178-83	5.1	88
330	The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2671-7	5.1	82
329	The authors reply. *Critical Care Medicine*, **2015**, 43, e154-5	1.4	
328	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. *Trials*, **2015**, 16, 24	2.8	46
327	Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring. *Infectious Diseases*, **2015**, 47, 739-42	3.1	6
326	Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. *Seminars in Respiratory and Critical Care Medicine*, **2015**, 36, 136-53	3.9	93
325	The impact of hospital and ICU organizational factors on outcome in critically ill patients: results from the Extended Prevalence of Infection in Intensive Care study. *Critical Care Medicine*, **2015**, 43, 519-26	1.4	128

324	Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis. *International Journal of Antimicrobial Agents*, **2015**, 45, 647-51	14.3	13
323	An UHPLC-MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. *Bioanalysis*, **2015**, 7, 2311-2319	2.1	5
322	Antibiotic dose optimization in critically ill patients. *Medicina Intensiva*, **2015**, 39, 563-72	1.2	27
321	Assays for therapeutic drug monitoring of β-lactam antibiotics: A structured review. *International Journal of Antimicrobial Agents*, **2015**, 46, 367-75	14.3	65
320	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6471-6	5.9	48
319	A simple LC-MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: application to a pilot pharmacokinetic study in humans. *Journal of Pharmaceutical and Biomedical Analysis*, **2015**, 105, 39-45	3.5	19
318	Interethnic differences in pharmacokinetics of antibacterials. *Clinical Pharmacokinetics*, **2015**, 54, 243-60	6.2	16
317	Can we use an ex vivo continuous hemofiltration model to describe the adsorption and elimination of meropenem and piperacillin?. *International Journal of Artificial Organs*, **2015**, 38, 419-24	1.9	11
316	Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. *Current Opinion in Critical Care*, **2015**, 21, 412-20	3.5	55
315	A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts. *PLoS Medicine*, **2015**, 12, e1001916	11.6	111
314	The Effect of Paracetamol on Core Body Temperature in Acute Traumatic Brain Injury: A Randomised, Controlled Clinical Trial. *PLoS ONE*, **2015**, 10, e0144740	3.7	16
313	Factors associated with vancomycin nephrotoxicity in the critically ill. *Anaesthesia and Intensive Care* , **2015**, 43, 594-9	1.1	31
312	Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. *Critical Care*, **2015**, 19, 28	10.8	86
311	Subtleties in practical application of prolonged infusion of β-lactam antibiotics. *International Journal of Antimicrobial Agents*, **2015**, 45, 461-3	14.3	24
310	A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. *Critical Care*, **2015**, 19, 84	10.8	86
309	Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling. *Bioanalysis*, **2015**, 7, 2585-95	2.1	36
308	To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt. *Current Opinion in Pharmacology*, **2015**, 24, 68-78	5.1	21
307	Antibiotic dose optimization in critically ill patients. *Medicina Intensiva (English Edition)*, **2015**, 39, 563-57	2.2	1

306	Pharmacokinetics of fluconazole in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. *International Journal of Antimicrobial Agents*, **2015**, 45, 192-5	14.3	5
305	Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. *International Journal of Antimicrobial Agents*, **2015**, 45, 41-5	14.3	33
304	Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1411-7	5.9	19
303	Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?. *Journal of Antimicrobial Chemotherapy* , **2015**, 70, 528-33	5.1	17
302	How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. *Diagnostic Microbiology and Infectious Disease*, **2015**, 82, 92-103	2.9	54
301	The Durban World Congress Ethics Round Table IV: health care professional end-of-life decision making. *Journal of Critical Care*, **2015**, 30, 224-30	4	20
300	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 1495-502	5.1	43
299	Seated and semi-recumbent positioning of the ventilated intensive care patient - effect on gas exchange, respiratory mechanics and hemodynamics. *Heart and Lung: Journal of Acute and Critical Care*, **2014**, 43, 105-11	2.6	12
298	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *Lancet Infectious Diseases, The*, **2014**, 14, 498-509	25.5	534
297	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study. *International Journal of Antimicrobial Agents*, **2014**, 43, 423-30	14.3	29
296	The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?. *Diagnostic Microbiology and Infectious Disease*, **2014**, 79, 77-84	2.9	43
295	A national survey of renal replacement therapy prescribing practice for acute kidney injury in Malaysian intensive care units. *Nephrology*, **2014**, 19, 507-12	2.2	10
294	Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3533-7	5.9	30
293	An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1416-23	5.1	144
292	DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?. *Clinical Infectious Diseases*, **2014**, 58, 1072-83	11.6	564
291	Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. *International Journal of Antimicrobial Agents*, **2014**, 44, 409-15	14.3	34
290	The Durban World Congress Ethics Round Table Conference Report: I. Differences between withholding and withdrawing life-sustaining treatments. *Journal of Critical Care*, **2014**, 29, 890-5	4	28
289	Reply to Rhodes et al. *Clinical Infectious Diseases*, **2014**, 59, 907-8	11.6	2

288	Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome. *BMC Infectious Diseases*, **2014**, 14, 420	4	64
287	Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. *Intensive Care Medicine*, **2014**, 40, 1340-51	14.5	112
286	The Durban World Congress Ethics Round Table Conference Report: II. Withholding or withdrawing of treatment in elderly patients admitted to the intensive care unit. *Journal of Critical Care*, **2014**, 29, 896-901	4	29
285	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. *Critical Care*, **2014**, 18, R99	10.8	65
284	Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. *International Journal of Antimicrobial Agents*, **2014**, 43, 343-8	14.3	32
283	Infections and use of antibiotics in patients admitted for severe acute pancreatitis: data from the EPIC II study. *Surgical Infections*, **2014**, 15, 394-8	2	19
282	Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. *International Journal of Antimicrobial Agents*, **2014**, 44, 163-7	14.3	21
281	Variable ganciclovir concentrations in a critically ill patient receiving continuous renal replacement therapy and plasma exchange?. *International Journal of Antimicrobial Agents*, **2014**, 43, 572-3	14.3	5
280	Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 2797-803	5.1	25
279	The Durban World Congress Ethics Round Table Conference Report: III. Withdrawing Mechanical ventilation--the approach should be individualized. *Journal of Critical Care*, **2014**, 29, 902-7	4	22
278	The authors reply. *Critical Care Medicine*, **2014**, 42, e675-6	1.4	
277	The authors reply. *Critical Care Medicine*, **2014**, 42, e602-3	1.4	
276	Tracheal cuff pressure monitoring in the ICU: a literature review and survey of current practice in Queensland. *Anaesthesia and Intensive Care*, **2014**, 42, 761-70	1.1	14
275	Select critically ill patients at risk of augmented renal clearance: experience in a Malaysian intensive care unit. *Anaesthesia and Intensive Care*, **2014**, 42, 715-22	1.1	20
274	How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?. *BMC Infectious Diseases*, **2014**, 14, 288	4	67
273	Low flucloxacillin concentrations in a patient with central nervous system infection: the need for plasma and cerebrospinal fluid drug monitoring in the ICU. *Annals of Pharmacotherapy*, **2014**, 48, 1380-4	2.9	14
272	Antimicrobial stewardship of β-lactams in intensive care units. *Expert Review of Anti-Infective Therapy*, **2014**, 12, 581-95	5.5	11
271	The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. *Advanced Drug Delivery Reviews*, **2014**, 77, 3-11	18.5	242

270	Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels. *BMC Infectious Diseases*, **2014**, 14, 513	4	12
269	The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. *Critical Care*, **2014**, 18, 565	10.8	66
268	Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. *Critical Care*, **2014**, 18, 657	10.8	50
267	Burn resuscitation--hourly urine output versus alternative endpoints: a systematic review. *Shock*, **2014**, 42, 295-306	3.4	40
266	The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. *Critical Care Medicine*, **2014**, 42, 1640-50	1.4	81
265	Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*. *Critical Care Medicine*, **2014**, 42, 2527-36	1.4	71
264	Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*. *Critical Care Medicine*, **2014**, 42, 520-7	1.4	181
263	A new marker of sepsis post burn injury?*. *Critical Care Medicine*, **2014**, 42, 2029-36	1.4	31
262	Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 2508-16	5.1	25
261	Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. *Lancet Respiratory Medicine,the*, **2014**, 2, 380-6	35.1	566
260	Principles of antibiotic use **2014**, 738-742.e1		
259	Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. *Minerva Anestesiologica*, **2014**, 80, 1302-9	1.9	23
258	What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. *International Journal of Antimicrobial Agents*, **2013**, 42, 289-93	14.3	54
257	Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 2600-8	5.1	36
256	Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 6165-70	5.9	137
255	Reply to Soman et al. *Clinical Infectious Diseases*, **2013**, 57, 323-4	11.6	
254	A comparison of CKD-EPI estimated glomerular filtration rate and measured creatinine clearance in recently admitted critically ill patients with normal plasma creatinine concentrations. *BMC Nephrology*, **2013**, 14, 250	2.7	35
253	Clinical implications of antibiotic pharmacokinetic principles in the critically ill. *Intensive Care Medicine*, **2013**, 39, 2070-82	14.5	150

252	Ampicillin/sulbactam: its potential use in treating infections in critically ill patients. *International Journal of Antimicrobial Agents*, **2013**, 42, 384-9	14.3	41
251	The clinical relevance of plasma protein binding changes. *Clinical Pharmacokinetics*, **2013**, 52, 1-8	6.2	173
250	Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. *Clinical Infectious Diseases*, **2013**, 56, 236-44	11.6	250
249	β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. *International Journal of Antimicrobial Agents*, **2013**, 41, 162-6	14.3	49
248	Phenytoin loading doses in adult critical care patients: does current practice achieve adequate drug levels?. *Anaesthesia and Intensive Care*, **2013**, 41, 602-9	1.1	4
247	Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. *International Journal of Antimicrobial Agents*, **2013**, 42, 90-3	14.3	17
246	Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?. *International Journal of Antimicrobial Agents*, **2013**, 41, 564-8	14.3	35
245	Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. *Critical Care*, **2013**, 17, R35	10.8	108
244	Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. *Critical Care*, **2013**, 17, R84	10.8	133
243	Molecular analysis of the Acinetobacter baumannii biofilm-associated protein. *Applied and Environmental Microbiology*, **2013**, 79, 6535-43	4.8	49
242	B-type natriuretic Peptide: not just a heart throb. *A & A Case Reports*, **2013**, 1, 59-61		
241	A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial. *BMJ Open*, **2013**, 3,	3	2
240	How should we dose antibiotics for pneumonia in the ICU?. *Current Opinion in Infectious Diseases*, **2013**, 26, 189-95	5.4	8
239	Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. *Clinical Infectious Diseases*, **2013**, 56, 471-7	11.6	113
238	Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. *Journal of Neurosurgery*, **2013**, 118, 297-301	3.2	31
237	Defining Antibiotic Dosing in Lung Infections. *Clinical Pulmonary Medicine*, **2013**, 20, 121-128	0.3	14
236	A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 2859-65	5.1	42
235	Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. *Critical Care Medicine*, **2013**, 41, 489-95	1.4	65

234	Identification of novel vaccine candidates against multidrug-resistant Acinetobacter baumannii. *PLoS ONE*, **2013**, 8, e77631	3.7	56
233	A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. *Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine*, **2013**, 15, 179-85	2.8	3
232	Review article: Part two: Goal-directed resuscitation--which goals? Perfusion targets. *EMA - Emergency Medicine Australasia*, **2012**, 24, 127-35	1.5	12
231	Review article: Part one: Goal-directed resuscitation--which goals? Haemodynamic targets. *EMA - Emergency Medicine Australasia*, **2012**, 24, 14-22	1.5	12
230	Ξlactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review. *Clinical and Experimental Pharmacology and Physiology*, **2012**, 39, 489-96	3	59
229	Hydroxyethyl starch or saline for fluid resuscitation in intensive care. *New England Journal of Medicine*, **2012**, 367, 1901-11	59.2	1127
228	Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. *Intensive Care Medicine*, **2012**, 38, 1930-45	14.5	226
227	A limited set of molecular biomarkers may provide superior diagnostic outcomes to procalcitonin in sepsis. *Critical Care*, **2012**, 16,	10.8	1
226	Characteristics of bloodstream infections in burn patients: An 11-year retrospective study. *Burns*, **2012**, 38, 685-90	2.3	40
225	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. *BMC Infectious Diseases*, **2012**, 12, 152	4	34
224	Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. *International Journal of Antimicrobial Agents*, **2012**, 39, 1-10	14.3	37
223	Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. *International Journal of Antimicrobial Agents*, **2012**, 39, 69-72	14.3	35
222	How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. *International Journal of Antimicrobial Agents*, **2012**, 39, 187-92	14.3	45
221	A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2012**, 907, 178-84	3.2	84
220	Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: a structured review. *Surgical Infections*, **2012**, 13, 9-17	2	16
219	Editorial commentary: Closing the loop--a colistin clinical study to confirm dosing recommendations from PK/PD modeling. *Clinical Infectious Diseases*, **2012**, 54, 1727-9	11.6	18
218	Continuous beta-lactam infusion in critically ill patients: the clinical evidence. *Annals of Intensive Care*, **2012**, 2, 37	8.9	66
217	Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. *Annals of Intensive Care*, **2012**, 2, 35	8.9	119

216	Blood culture collection in patients with acute kidney injury receiving renal replacement therapy: an observational study. *Anaesthesia and Intensive Care*, **2012**, 40, 813-9	1.1	3
215	A comparison of pulse contour wave analysis and ultrasonic cardiac output monitoring in the critically ill. *Anaesthesia and Intensive Care*, **2012**, 40, 631-7	1.1	8
214	Importance of High Creatinine Clearance for Antibacterial Treatment in Sepsis **2012**, 171-197		
213	Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. *Current Opinion in Critical Care*, **2012**, 18, 460-71	3.5	68
212	Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study). *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1249-56	6.9	16
211	Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study. *Therapeutic Drug Monitoring*, **2012**, 34, 160-4	3.2	46
210	Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. *Critical Care Medicine*, **2012**, 40, 1523-8	1.4	151
209	Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. *Chest*, **2012**, 142, 30-39	5.3	277
208	The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection. *PLoS ONE*, **2012**, 7, e38719	3.7	19
207	Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics. *Minerva Anestesiologica*, **2012**, 78, 94-104	1.9	26
206	Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. *Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine*, **2012**, 14, 312-5	2.8	13
205	Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. *International Journal of Antimicrobial Agents*, **2011**, 37, 90-2	14.3	6
204	Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. *International Journal of Antimicrobial Agents*, **2011**, 38, 331-5	14.3	109
203	Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. *Critical Care Clinics*, **2011**, 27, 19-34	4.5	96
202	The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. *Clinical Pharmacokinetics*, **2011**, 50, 99-110	6.2	238
201	Pharmacokinetic evaluation of fluconazole in critically ill patients. *Expert Opinion on Drug Metabolism and Toxicology*, **2011**, 7, 1431-40	5.5	11
200	Antimicrobial utilisation in 37 Australian and New Zealand intensive care units. *Anaesthesia and Intensive Care*, **2011**, 39, 231-7	1.1	14
199	The critical care costs of the influenza A/H1N1 2009 pandemic in Australia and New Zealand. *Anaesthesia and Intensive Care*, **2011**, 39, 384-91	1.1	19

198	Experience with high frequency oscillation ventilation during the 2009 H1N1 influenza pandemic in Australia and New Zealand. *Anaesthesia and Intensive Care*, **2011**, 39, 837-46	1.1	4
197	Sustained low efficiency dialysis allows rational renal replacement therapy, but does it allow rational drug dosing?. *Critical Care Medicine*, **2011**, 39, 602-3	1.4	18
196	Determining authorship in multicenter trials: a systematic review. *Acta Anaesthesiologica Scandinavica*, **2011**, 55, 1037-43	1.9	11
195	Pitfalls of using estimations of glomerular filtration rate in an intensive care population. *Internal Medicine Journal*, **2011**, 41, 537-43	1.6	50
194	Prior statin use is not associated with improved outcome in emergency patients admitted with infection: a prospective observational study. *Academic Emergency Medicine*, **2011**, 18, 127-34	3.4	7
193	Implications of augmented renal clearance in critically ill patients. *Nature Reviews Nephrology*, **2011** , 7, 539-43	14.9	120
192	The role of surveillance cultures in the prediction of susceptibility patterns of Gram-negative bacilli in the intensive care unit. *European Journal of Clinical Microbiology and Infectious Diseases*, **2011**, 30, 739-44	5.3	12
191	The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality. *Intensive Care Medicine*, **2011**, 37, 816-23	14.5	29
190	Antibiotic dosing in the ‹at risk› critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. *BMC Anesthesiology*, **2011**, 11, 3	2.4	33
189	The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery. *BMC Anesthesiology*, **2011**, 11, 5	2.4	6
188	A prospective registry of emergency department patients admitted with infection. *BMC Infectious Diseases*, **2011**, 11, 27	4	6
187	A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. *Critical Care*, **2011**, 15, R139	10.8	138
186	Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. *Critical Care*, **2011**, 15, R149	10.8	101
185	Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 227-31	5.1	104
184	Physiological changes in the critically ill patient with sepsis. *Current Pharmaceutical Biotechnology*, **2011**, 12, 1991-5	2.6	22
183	ARC--augmented renal clearance. *Current Pharmaceutical Biotechnology*, **2011**, 12, 2020-9	2.6	27
182	Remote care by telemedicine in the ICU: many models of care can be effective. *Current Opinion in Critical Care*, **2011**, 17, 634-40	3.5	16
181	Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 5238-42	5.9	55

180	Antibiotic dosing in multiple organ dysfunction syndrome. *Chest*, **2011**, 139, 1210-1220	5.3	70
179	Effect of intravenous GLutamine supplementation IN Trauma patients receiving enteral nutrition study protocol (GLINT Study): a prospective, blinded, randomised, placebo-controlled clinical trial. *BMJ Open*, **2011**, 1, e000334	3	9
178	Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 5868-73	5.9	38
177	Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 2704-9	5.9	159
176	Candida Pneumonia in Patients with Hematological Neoplasia **2011**, 349-356		1
175	Can learning to sustain life be BASIC? Teaching for the initial management of the critically ill in Australia and New Zealand. *Anaesthesia and Intensive Care*, **2010**, 38, 1043-51	1.1	3
174	Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 1771-8	5.1	83
173	Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2974-8	5.9	56
172	Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 1276-85	5.1	67
171	Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 3635-40	5.9	53
170	Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill. *Current Respiratory Medicine Reviews*, **2010**, 6, 253-263	0.3	
169	Respiratory Burns: A Clinical Review. *Current Respiratory Medicine Reviews*, **2010**, 6, 285-291	0.3	
168	Control of an outbreak of carbapenem-resistant Acinetobacter baumannii in Australia after introduction of environmental cleaning with a commercial oxidizing disinfectant. *Infection Control and Hospital Epidemiology*, **2010**, 31, 418-20	2	34
167	First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. *International Journal of Antimicrobial Agents*, **2010**, 35, 156-63	14.3	133
166	Augmented renal clearance in the Intensive Care Unit: an illustrative case series. *International Journal of Antimicrobial Agents*, **2010**, 35, 606-8	14.3	69
165	Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. *International Journal of Antimicrobial Agents*, **2010**, 36, 332-9	14.3	243
164	Antimicrobial chemotherapy and lung microdialysis: a review. *International Journal of Antimicrobial Agents*, **2010**, 36, 491-500	14.3	33
163	Management of invasive candidiasis in the intensive care unit. *Drugs*, **2010**, 70, 823-39	12.1	21

162	Augmented renal clearance: implications for antibacterial dosing in the critically ill. *Clinical Pharmacokinetics*, **2010**, 49, 1-16	6.2	245
161	Augmented renal clearance in traumatic brain injury. *Critical Care*, **2010**, 14, P521	10.8	2
160	A novel molecular biomarker diagnostic for the early detection of sepsis. *Critical Care*, **2010**, 14, P9	10.8	1
159	Pharmacokinetic evaluation of piperacillin-tazobactam. *Expert Opinion on Drug Metabolism and Toxicology*, **2010**, 6, 1017-31	5.5	50
158	Principles of antibacterial dosing in continuous renal replacement therapy. *Blood Purification*, **2010**, 30, 195-212	3.1	49
157	Preventive Strategies for Ventilator Associated Pneumonia. *Current Respiratory Medicine Reviews*, **2010**, 6, 238-252	0.3	3
156	Optimizing Antibiotic Use in the Intensive Care Unit. *Clinical Pulmonary Medicine*, **2010**, 17, 162-169	0.3	0
155	Prophylaxis, empirical and preemptive treatment of invasive candidiasis. *Current Opinion in Critical Care*, **2010**, 16, 470-4	3.5	26
154	Pharmacokinetics and pharmacodynamics in critically ill patients. *Current Opinion in Anaesthesiology* , **2010**, 23, 472-8	2.9	37
153	Do burn patients cost more? The intensive care unit costs of burn patients compared with controls matched for length of stay and acuity. *Journal of Burn Care and Research*, **2010**, 31, 598-602	0.8	21
152	Augmented creatinine clearance in traumatic brain injury. *Anesthesia and Analgesia*, **2010**, 111, 1505-10	3.9	85
151	Assessment of peripheral arterial catheters as a source of sepsis in the critically ill: a narrative review. *Journal of Hospital Infection*, **2010**, 75, 12-8	6.9	22
150	Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2010**, 878, 2039-43	3.2	144
149	Pitfalls of using estimations of glomerular filtration rate in an intensive care population. *Internal Medicine Journal*, **2010**,	1.6	5
148	Augmented Renal Clearance: Unraveling the Mystery of Elevated Antibiotic Clearance. *Yearbook of Intensive Care and Emergency Medicine*, **2010**, 495-506		
147	Augmented Renal Clearance: Unraveling the Mystery of Elevated Antibiotic Clearance **2010**, 495-506		0
146	A detailed feeding algorithm improves delivery of nutrition support in an intensive care unit. *Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine*, **2010**, 12, 149-55	2.8	2
145	A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units. *Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine*, **2010**, 12, 162-70	2.8	7

144	Predictors and outcome associated with an Enterococcus positive isolate during intensive care unit admission. *Anaesthesia and Intensive Care*, **2009**, 37, 976-82	1.1	2
143	Airway obstruction due to a pre-vertebral haematoma following difficult central line insertion--implications for ultrasound guidance and review of the literature. *Anaesthesia and Intensive Care*, **2009**, 37, 309-13	1.1	8
142	Tissue accumulation of cephalothin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalothin concentrations in burn patients and healthy volunteers. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 210-5	5.9	11
141	Unbound cephalothin pharmacokinetics in adult burn patients are related to the elapsed time after injury. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 5303-5	5.9	7
140	Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. *Intensive Care Medicine*, **2009**, 35, 2141-5	14.5	39
139	Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study. *BMC Nephrology*, **2009**, 10, 42	2.7	8
138	Point of care measurement of plasma creatinine in critically ill patients with acute kidney injury. *Anaesthesia*, **2009**, 64, 403-7	6.6	30
137	Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. *Journal of Antimicrobial Chemotherapy*, **2009**, 64, 142-50	5.1	238
136	Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. *International Journal of Antimicrobial Agents*, **2009**, 33, 554.e1-7	14.3	47
135	Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis. *International Journal of Antimicrobial Agents*, **2009**, 34, 383-4	14.3	5
134	A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?. *Journal of Antimicrobial Chemotherapy*, **2009**, 64, 929-37	5.1	68
133	Management of meningitis due to antibiotic-resistant Acinetobacter species. *Lancet Infectious Diseases, The*, **2009**, 9, 245-55	25.5	152
132	International study of the prevalence and outcomes of infection in intensive care units. *JAMA - Journal of the American Medical Association*, **2009**, 302, 2323-9	27.4	2023
131	Pharmacokinetic issues for antibiotics in the critically ill patient. *Critical Care Medicine*, **2009**, 37, 840-51; quiz 859	1.4	598
130	Principles of antibacterial dosing in continuous renal replacement therapy. *Critical Care Medicine*, **2009**, 37, 2268-82	1.4	280
129	Dose matters: Dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy. *Critical Care Medicine*, **2009**, 37, 2491-2492	1.4	
128	Midazolam Metabolism: Implications for Individualised Dosing?. *Journal of Pharmacy Practice and Research*, **2009**, 39, 198-201	0.7	3
127	A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. *Critical Care Medicine*, **2009**, 37, 2071-8	1.4	208

126	Tissue Distribution of Beta-Lactam Antibiotics: Continuous versus Bolus Dosing. *Journal of Pharmacy Practice and Research*, **2009**, 39, 219-222	0.7	5
125	Respiratory Complications in Burns. *Clinical Pulmonary Medicine*, **2009**, 16, 132-138	0.3	8
124	Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?. *Critical Care Medicine*, **2009**, 37, 926-33	1.4	136
123	The microcirculation, regional blood flow and tissue oxygenation: will new technologies drive new resuscitation goals?. *Anaesthesia and Intensive Care*, **2009**, 37, 700-2	1.1	1
122	Principles of Pharmacology in the Critically Ill **2009**, 31-36		
121	A new paradigm for treating infections: "go hard and go home". *Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine*, **2009**, 11, 276-81	2.8	7
120	Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. *Anaesthesia*, **2008**, 63, 714-8	6.6	10
119	A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis. *International Journal of Antimicrobial Agents*, **2008**, 31, 240-4	14.3	9
118	Increased fluid resuscitation can lead to adverse outcomes in major-burn injured patients, but low mortality is achievable. *Burns*, **2008**, 34, 1090-7	2.3	77
117	Antibiotic resistance--whatIs dosing got to do with it?. *Critical Care Medicine*, **2008**, 36, 2433-40	1.4	239
116	Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. *Current Opinion in Critical Care*, **2008**, 14, 390-6	3.5	75
115	Continuous Infusion of Time-dependent Antibiotics. *Clinical Pulmonary Medicine*, **2008**, 15, 167-172	0.3	1
114	Does severe non-infectious SIRS differ from severe sepsis? Results from a multi-centre Australian and New Zealand intensive care unit study. *Intensive Care Medicine*, **2008**, 34, 1654-61	14.5	54
113	A comparison of epinephrine and norepinephrine in critically ill patients. *Intensive Care Medicine*, **2008**, 34, 2226-34	14.5	216
112	Dose Adjustment and Pharmacodynamic Considerations for Antibiotics in Severe Sepsis and Septic Shock **2008**, 97-136		2
111	Prehospital Care **2008**, 307-319		1
110	Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. *International Journal of Antimicrobial Agents*, **2007**, 29, 117-28	14.3	19
109	Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. *International Journal of Antimicrobial Agents*, **2007**, 30, 11-8	14.3	132

108	Acute respiratory distress in a bleomycin primed patient: a new use for nitric oxide. *Anaesthesia and Intensive Care*, **2007**, 35, 86-90	1.1	1
107	Autonomic dysfunction in tetanus - what lessons can be learnt with specific reference to alpha-2 agonists?. *Anaesthesia*, **2007**, 62, 1066-70	6.6	21
106	Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. *Intensive Care Medicine*, **2007**, 33, 781-788	14.5	32
105	Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. *Journal of Antimicrobial Chemotherapy*, **2007**, 59, 285-91	5.1	91
104	The entrapped central venous catheter. *British Journal of Anaesthesia*, **2007**, 98, 89-92	5.4	9
103	Optimizing use of beta-lactam antibiotics in the critically ill. *Seminars in Respiratory and Critical Care Medicine*, **2007**, 28, 579-85	3.9	16
102	Inadequate antimicrobial prophylaxis during surgery: a study of beta-lactam levels during burn debridement. *Journal of Antimicrobial Chemotherapy*, **2007**, 60, 166-9	5.1	15
101	Entrapped central venous catheter. *British Journal of Anaesthesia*, **2007**, 98, 695; author reply 695	5.4	
100	Returning to the pre-antibiotic era in the critically ill: the XDR problem. *Critical Care Medicine*, **2007**, 35, 1789-91	1.4	28
99	Resistance in the intensive care unit: whose problem is it and how can intensivists help?. *Critical Care Medicine*, **2007**, 35, 299-301	1.4	4
98	Lateral positioning of ventilated intensive care patients: a study of oxygenation, respiratory mechanics, hemodynamics, and adverse events. *Heart and Lung: Journal of Acute and Critical Care*, **2007**, 36, 277-86	2.6	32
97	Dose Adjustment and Pharmacokinetics of Antibiotics in Severe Sepsis and Septic Shock **2007**, 122-146		
96	Prescription of Antimicrobial Agents in Patients Undergoing Continuous Renal Replacement Therapy **2007**, 147-158		
95	The implications of enterococci for the intensive care unit. *Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine*, **2007**, 9, 69-75	2.8	9
94	Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. *Journal of Antimicrobial Chemotherapy*, **2006**, 58, 987-93	5.1	80
93	Positioning practices for ventilated intensive care patients: current practice, indications and contraindications. *Australian Critical Care*, **2006**, 19, 122-6, 128, 130-2	2.9	22
92	Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. *Clinical Pharmacokinetics*, **2006**, 45, 755-73	6.2	205
91	Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. *International Journal of Antimicrobial Agents*, **2006**, 28, 147-50	14.3	27

90	Manual hyperinflation causes norepinephrine release. *Heart and Lung: Journal of Acute and Critical Care*, **2006**, 35, 262-8	2.6	6
89	Estimate of the number of patients eligible for treatment with drotrecogin alfa (activated) based on differing international indications: post-hoc analysis of an inception cohort study in Australia and New Zealand. *Anaesthesia and Intensive Care*, **2006**, 34, 184-90	1.1	1
88	Making the wrong choice: Consequences for patients with infections due to methicillin-resistant Staphylococcus aureus. *Critical Care Medicine*, **2006**, 34, 2239-41	1.4	4
87	Low mannose-binding lectin function is associated with sepsis in adult patients. *FEMS Immunology and Medical Microbiology*, **2006**, 48, 274-82		43
86	The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. *Critical Care*, **2005**, 9, R710-7	10.8	34
85	Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. *International Journal of Antimicrobial Agents*, **2005**, 26, 50-5	14.3	40
84	Is the end-game penetration (of the airway)?. *Critical Care Medicine*, **2005**, 33, 1654-5	1.4	25
83	Disease risk and mortality prediction in intensive care patients with pneumonia. Australian and New Zealand practice in intensive care (ANZPIC II). *Anaesthesia and Intensive Care*, **2005**, 33, 101-11	1.1	17
82	The costs of caring for patients in a tertiary referral Australian Intensive Care Unit. *Anaesthesia and Intensive Care*, **2005**, 33, 477-82	1.1	40
81	Antibiotic resistance in the intensive care unit: a primer in bacteriology. *Anaesthesia and Intensive Care*, **2005**, 33, 188-95	1.1	
80	Predictors of physician confidence to diagnose pneumonia and determine illness severity in ventilated patients. Australian and New Zealand practice in intensive care (ANZPIC II). *Anaesthesia and Intensive Care*, **2005**, 33, 112-9	1.1	9
79	The spectrum of practice in the diagnosis and management of pneumonia in patients requiring mechanical ventilation. Australian and New Zealand practice in intensive care (ANZPIC II). *Anaesthesia and Intensive Care*, **2005**, 33, 87-100	1.1	15
78	Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 4814-5	5.9	108
77	Serum procalcitonin and C-reactive protein as markers of sepsis and outcome in patients with neurotrauma and subarachnoid haemorrhage. *Anaesthesia and Intensive Care*, **2004**, 32, 465-70	1.1	47
76	Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. *British Journal of Clinical Pharmacology*, **2004**, 58, 259-68	3.8	86
75	Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. *Intensive Care Medicine*, **2004**, 30, 589-96	14.5	296
74	A randomised controlled study of the efficacy of hypromellose and Lacri-Lube combination versus polyethylene/Cling wrap to prevent corneal epithelial breakdown in the semiconscious intensive care patient. *Intensive Care Medicine*, **2004**, 30, 1122-6	14.5	58
73	Routine changing of intravenous administration sets does not reduce colonization or infection in central venous catheters. *Infection Control and Hospital Epidemiology*, **2004**, 25, 650-5	2	29

72	The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration an in vitro study of levofloxacin. *International Journal of Antimicrobial Agents*, **2004**, 24, 468-72	14.3	23
71	The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltrationAn in vitro study of levofloxacin. *International Journal of Antimicrobial Agents*, **2004**, 24, 468-472	14.3	41
70	Cefepime versus cefpirome: the importance of creatinine clearance. *Anesthesia and Analgesia*, **2003** , 97, 1149-1154	3.9	68
69	Pharmacological principles of antibiotic prescription in the critically ill. *Anaesthesia and Intensive Care*, **2002**, 30, 134-44	1.1	88
68	High dependency units: issues to consider in their planning. *Anaesthesia and Intensive Care*, **2002**, 30, 348-54	1.1	16
67	Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?. *Intensive Care Medicine*, **2002**, 28, 493-500	14.5	28
66	Intravascular administration sets are accurate and in appropriate condition after 7 days of continuous use: an in vitro study. *Journal of Advanced Nursing*, **2002**, 37, 330-7	3.1	6
65	Continuous measurement of cerebral blood flow velocity using transcranial Doppler reveals significant moment-to-moment variability of data in healthy volunteers and in patients with subarachnoid hemorrhage. *Critical Care Medicine*, **2002**, 30, 563-9	1.4	27
64	Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. *Intensive Care Medicine*, **2001**, 27, 363-70	14.5	60
63	Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. *Intensive Care Medicine*, **2001**, 27, 665-72	14.5	37
62	The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. *Journal of Antimicrobial Chemotherapy*, **2001**, 47, 421-9	5.1	140
61	Subcutaneous oxygen tensions provide similar information to ileal luminal CO2 tensions in an animal model of haemorrhagic shock. *Intensive Care Medicine*, **2000**, 26, 592-600	14.5	30
60	The treatment of tetanus with intrathecal baclofen. *Anaesthesia and Intensive Care*, **2000**, 28, 438-42	1.1	15
59	Can we achieve consensus on central venous catheter-related infections?. *Anaesthesia and Intensive Care*, **2000**, 28, 475-90	1.1	31
58	Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. *Clinical Infectious Diseases*, **2000**, 31, 1131-3	11.6	43
57	Towards better ICU antibiotic dosing. *Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine*, **2000**, 2, 282-9	2.8	1
56	Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. *Antimicrobial Agents and Chemotherapy*, **1999**, 43, 2559-61	5.9	98
55	Small tidal volume ventilation using a zero deadspace tracheal tube. *British Journal of Anaesthesia*, **1999**, 82, 213-6	5.4	4

54	Continuous infusion ceftazidime in intensive care: a randomized controlled trial. *Journal of Antimicrobial Chemotherapy*, **1999**, 43, 309-11	5.1	72
53	Acute respiratory distress syndrome precipitated by transjugular intrahepatic porto-systemic shunting for severe hepatic veno-occlusive disease. Is it due to pulmonary leucostasis?. *Intensive Care Medicine*, **1999**, 25, 1332-3	14.5	5
52	Inter observer variability of the transcranial Doppler ultrasound technique: impact of lack of practice on the accuracy of measurement. *Journal of Clinical Monitoring and Computing*, **1999**, 15, 179-84	2	47
51	Keeping relatives informed by the internet. *Lancet, The*, **1999**, 354, 517-8	40	
50	Vancomycin resistance in gram-positive cocci--old bugs, new tricks, confusing terminology. *Anaesthesia and Intensive Care*, **1999**, 27, 396-9	1.1	
49	Critical care research and pre-emptive informed consent: a practical approach used in Chris Hani Baragwanath ICU. *Intensive Care Medicine*, **1998**, 24, 353-7	14.5	10
48	Good clinical research practice: what is it and is it possible in the intensive care unit?. *Anaesthesia and Intensive Care*, **1998**, 26, 568-74	1.1	1
47	Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 2235-9	5.9	77
46	Intermittent bolus dosing of ceftazidime in critically ill patients. *Journal of Antimicrobial Chemotherapy*, **1997**, 40, 269-73	5.1	70
45	Critical care in Africa. North to south and the future with special reference to southern Africa. *Critical Care Clinics*, **1997**, 13, 255-65	4.5	14
44	Gastric intramucosal pH and blood lactate in severe sepsis. *Anaesthesia*, **1997**, 52, 726-32	6.6	19
43	Performance of the Pediatric Risk of Mortality Score. *Critical Care Medicine*, **1997**, 25, 717	1.4	
42	Pitfalls in the prediction of renal function in the intensive care unit. A review. *South African Journal of Surgery*, **1997**, 35, 16-9	0.4	8
41	Measurements of glomerular filtration in the intensive care unit are only a rough guide to renal function. *South African Journal of Surgery*, **1997**, 35, 20-3	0.4	27
40	Predictors of mortality in severe malaria: a two year experience in a non-endemic area. *Anaesthesia and Intensive Care*, **1996**, 24, 217-23	1.1	33
39	Acute stridor as a presentation of bilateral abductor vocal cord paralysis. *Anaesthesia*, **1996**, 51, 1046-8	6.6	4
38	A guideline for competency of the critical care nurse. *American Journal of Critical Care*, **1996**, 5, 217-226	1.7	13
37	Development and validation of a critical care patient classification system. *American Journal of Critical Care*, **1996**, 5, 282-288	1.7	2

36	Poor discriminatory performance of the Pediatric Risk of Mortality (PRISM) score in a South African intensive care unit. *Critical Care Medicine*, **1996**, 24, 1507-13	1.4	37
35	Accidental intra-arterial adrenaline administration. *Anaesthesia and Intensive Care*, **1995**, 23, 488-9	1.1	2
34	Failed nasogastric intubation in undiagnosed carcinoma of the oesophagus. *Anaesthesia and Intensive Care*, **1995**, 23, 370-2	1.1	
33	Changes in vancomycin pharmacokinetics in critically ill infants. *Anaesthesia and Intensive Care*, **1995**, 23, 678-82	1.1	45
32	Emergency percutaneous balloon mitral valvotomy in a patient with septic shock. *Chest*, **1995**, 108, 570-2	5.3	2
31	Paralytic ileus as a complication of atropine therapy following severe organophosphate poisoning. *Anaesthesia*, **1994**, 49, 791-3	6.6	6
30	A double-blind comparison of vecuronium administered by the Springfusor infusion device to vecuronium by intermittent bolus injection in critically ill adult patients. *Anaesthesia and Intensive Care*, **1994**, 22, 580-5	1.1	4
29	Malignant astrocytoma of the cervico-medullary junction masquerading as Guillain-Barr syndrome. *Postgraduate Medical Journal*, **1994**, 70, 499-502	2	0
28	Haemodynamic and oxygen transport response during exchange transfusion for severe falciparum malaria. *Postgraduate Medical Journal*, **1994**, 70, 801-4	2	9
27	Decreased cardiac index as an indicator of tension pneumothorax in the ventilated patient. *Anaesthesia*, **1994**, 49, 137-41	6.6	14
26	A comparison of arterial lines and insertion techniques in critically ill patients. *Anaesthesia*, **1994**, 49, 968-73	6.6	21
25	Esmolol in a case of severe tetanus. Adequate haemodynamic control achieved despite markedly elevated catecholamine levels. *South African Journal of Surgery*, **1994**, 32, 33-5	0.4	4
24	Successful use of continuous veno-venous haemofiltration to treat profound fluid retention in severe peripartum cardiomyopathy. *Anaesthesia*, **1993**, 48, 1065-7	6.6	10
23	Acute lung injury at Baragwanath ICU. An eight-month audit and call for consensus for other organ failure in the adult respiratory distress syndrome. *Chest*, **1993**, 103, 1832-6	5.3	16
22	Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. *Chest*, **1993**, 104, 389-92	5.3	117
21	Intensive care utilisation: the Baragwanath experience. *Anaesthesia and Intensive Care*, **1993**, 21, 396-9	1.1	7
20	High-dose adrenaline in adult in-hospital asystolic cardiopulmonary resuscitation: a double-blind randomised trial. *Anaesthesia and Intensive Care*, **1993**, 21, 192-6	1.1	40
19	Renal replacement therapy for the critically ill--precarious progress. Part II. Technical aspects and clinical application. *South African Journal of Surgery*, **1993**, 31, 147-51	0.4	4

18	Renal replacement therapy for the critically ill--precarious progress. Part I. Definitions and physiological aspects. *South African Journal of Surgery*, **1993**, 31, 114-20	0.4	4
17	Septic shock: does adrenaline have a role as a first-line inotropic agent?. *Anaesthesia and Intensive Care*, **1992**, 20, 470-4	1.1	37
16	Erythropoietin in a patient following multiple trauma. *Anaesthesia*, **1992**, 47, 962-4	6.6	20
15	Comparison of disease severity scoring systems in septic shock. *Critical Care Medicine*, **1991**, 19, 1165-71	1.4	30
14	The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. *Journal of Antimicrobial Chemotherapy*, **1991**, 27 Suppl C, 81-9	5.1	55
13	A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. *Journal of Antimicrobial Chemotherapy*, **1991**, 28, 753-64	5.1	107
12	Typhoid fever: an undescribed cause of adult respiratory distress syndrome. *Anaesthesia and Intensive Care*, **1991**, 19, 124-6	1.1	5
11	Vasoconstrictor effects of adrenaline in human septic shock. *Anaesthesia and Intensive Care*, **1991**, 19, 61-5	1.1	46
10	Acute preload effects of furosemide. *Chest*, **1990**, 98, 124-8	5.3	23
9	Coronary embolism causing myocardial infarction. *Intensive Care Medicine*, **1990**, 16, 215-6	14.5	30
8	Difficulty in weaning from respiratory support in a patient with the intermediate syndrome of organophosphate poisoning. *Critical Care Medicine*, **1989**, 17, 1075-6	1.4	12
7	Catheter related infection. A plea for consensus with review and guidelines. *Intensive Care Medicine* , **1988**, 14, 503-9	14.5	34
6	Fatal infection caused by a multiply resistant type 3 pneumococcus. *Journal of Clinical Microbiology*, **1988**, 26, 1590-1	9.7	8
5	Autonomic dysfunction in severe tetanus. *Critical Care Medicine*, **1987**, 15, 987-988	1.4	56
4	Pitfalls in the interpretation of pulmonary capillary wedge pressure. *South African Medical Journal*, **1985**, 67, 174-7	1.5	7
3	Vitamin B12 levels in the prolonged use of sodium nitroprusside. *Critical Care Medicine*, **1984**, 12, 161-3	1.4	4
2	Intravenous Calcium chloride as an antidote to verapamil-induced hypotension. *Intensive Care Medicine*, **1982**, 8, 55-7	14.5	35
1	Use and Abuse of Antibiotics128-136		